Last Updated: 07/30/2014 01:41:43
TAN Stock Chart - 1 Month
TAN Stock Chart - 3 Month
TAN Stock Chart - 6 Month
TAN Stock Chart - 1 Year
TAN Stock Chart - 2 Year
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Tick Tock: Investors, Your Clock's Running Out We're not talking about your everyday hiccup here. Insulet Corporation (NASDAQ: PODD) investors have some major decisions to make fast. If there's one deadline you can't afford to sleep through, it's the one coming up on August 31, 2026. That's when folks who've taken a hit investing in Insulet are up to their necks in legal...
Continue Reading
Essential Strategies for Staying Cool This Summer on a Budget C & C Heating & Air Conditioning emphasizes a comprehensive approach to reducing energy consumption and maintaining sustainability. C & C Heating & Air Conditioning, a renowned heating and cooling service provider with over seventy years of industry experience, suggests that homeowners can enjoy a cooler...
Continue Reading
F.N.B. Corporation Dividend Announcement F.N.B. Corporation (NYSE: FNB) has officially announced the declaration of a quarterly cash dividend, set at $0.12 per share for its common stock. This move reflects the corporation's strong commitment to rewarding its shareholders and maintaining a solid financial foundation. Details of the Dividend Declaration The dividend is...
Continue Reading
Understanding Visa's Market Position In a world driven by financial innovation and fierce competition, it's essential for investors and enthusiasts to closely examine the players in the financial services sector. This article delves into Visa (NYSE: V) and contrasts its performance against that of its main competitors. By looking at crucial financial metrics, market...
Continue Reading
Ethereum's Remarkable Growth and Staking Potential The digital currency scene is buzzing with excitement as Ethereum spot ETFs have recorded impressive weekly inflows reaching $515 million, a notable first in history. This surge in investment highlights Ethereum's growing reputation as a reliable asset favored alike by institutional and retail investors. The Impact of...
Continue Reading